Catheter-Directed Thrombolysis Market Size

Catheter-Directed Thrombolysis Market Analysis

The catheter-directed thrombolysis market is expected to grow at a CAGR of 4.2% over the forecast period.

Due to the high infection rate and lockdown regulations brought on by the COVID-19 pandemic, surgical procedures were affected tremendously. For instance, according to a March 2022 research study published in the National Library of Medicine, there was a 52.7% reduction in adult cardiac surgery volume and a 65.5% reduction in elective cases between February 2020 to January 2021, which indicated an adverse impact of COVID-19 on the cardiac surgical procedures in its initial phase. However, as the COVID-19 cases subsided in the latter stage, the market started to recover, leading to an increase in surgeries. For instance, in December 2021, a press release published by the Albanian Daily stated that in the first eight months of 2021, the number of cases treated in cardiac surgery had increased by 11% compared to the same period in 2020, according to data from the monitoring report of the Ministry of Health. Thus, receding COVID-19 cases led to an increasing number of heart surgeries, which increased the adoption of minimally invasive treatments such as catheter directed thrombolysis. Similarly, various companies were engaged in new product development, contributing to market growth. For instance, in February 2022, CERENOVUS, part of Johnson & Johnson Medical Devices Companies, launched EMBOGUARD, a next-generation balloon guide catheter to be used in endovascular procedures, including those for patients with acute ischemic stroke. Thus, as per the analysis, the pandemic affected the market's growth adversely in its preliminary phase; however, the market gained significant traction due to the surge in the number of cardiac procedures with respect to thrombolysis and growing product launches.

The catheter directed thrombolytic market is expected to witness significant growth over the forecast period. The primary driving factors for the growth of the market include an increase in the prevalence of peripheral artery disease (PAD), deep vein thrombosis, and pulmonary embolism, among others. For instance, according to a research study published by Aaron W. Aday and Kunihiro Matsushita in June 2021, atherosclerotic lower extremity peripheral artery disease (PAD) is one of the major factors responsible for cardiovascular morbidity and mortality, and it affects about 8.5 million adults in the United States, with a prevalence rate of 7%. This high prevalence of PAD is expected to increase the number of atherectomy procedures, which is anticipated to fuel the growth of the studied market. Similarly, according to the September 2021 update by the CDC, the major risk factors for PAD are smoking, high blood pressure, atherosclerosis, diabetes, high cholesterol, and age above 60 years. Further, as per the same source, approximately 6.5 million people aged 40 years and older in the United States have PAD. Thus, with the growing prevalence of risk factors and an aging population in the country, the burden of PAD is further expected to increase, which is expected to have a significant positive impact on the growth of the catheter-directed thrombolysis market.

Furthermore, product approvals for the use of catheters in thrombolytic procedures are expected to propel the market's growth as they increase the presence of innovative products in the market space, which, in turn, bolsters the success rate of the surgeries. For instance, in May 2022, Genesis MedTech Group and Shockwave Medical successfully obtained approval from China's National Medical Products Administration (NMPA) to market and sell the Shockwave intravascular lithotripsy (IVL) system with the Shockwave C2 coronary IVL catheters and the Shockwave M5 and S4 peripheral IVL catheters in China. Thus, increased heart disease and product approvals are expected to boost market growth over the forecast period.

However, stringent regulatory procedures and the high cost of product development are likely to hinder the market growth.